Overview

Flexible-Dose Trial in Early Parkinson's Disease (PD)

Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy, safety, tolerability and pharmacokinetics (PK) of flexible doses of tavapadon in participants with Parkinson's Disease.
Phase:
Phase 3
Details
Lead Sponsor:
Cerevel Therapeutics, LLC